Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.63 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their clinical developments. They are focused on upcoming data that could impact future growth.
Management highlighted ongoing progress in clinical trials.
They emphasized the importance of upcoming data releases.
There was a focus on maintaining operational efficiency.
Protagonist Therapeutics reported a loss per share of $0.63, but the stock rose by 1.46%. Investors may be reacting positively to management's comments about ongoing clinical trials and potential future data releases, despite the lack of revenue information and guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CRINETICS PHARMACEUT
Mar 9, 2020